Values as of: 2025-02-10
COMMON STOCK | Biotechnology |
Last Closing
USD 3.23Change
-0.27 (-7.71)%Market Cap
USD 0.08BVolume
0.45MAnalyst Target
USD 8.00Verdict
Verdict
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Company Website : https://www.agenusbio.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+0.65 (+0.14%) |
USD 118.90B |
| REGN | Regeneron Pharmaceuticals Inc |
-19.64 (-2.77%) |
USD 73.95B |
| ARGX | argenx NV ADR |
-0.19 (-0.03%) |
USD 40.41B |
| ALNY | Alnylam Pharmaceuticals Inc |
-2.13 (-0.77%) |
USD 34.99B |
| ONC | BeiGene, Ltd. |
-3.83 (-1.71%) |
USD 25.62B |
| RPRX | Royalty Pharma Plc |
-0.01 (-0.03%) |
USD 18.12B |
| SMMT | Summit Therapeutics PLC |
+0.39 (+1.94%) |
USD 17.52B |
| UTHR | United Therapeutics Corporatio.. |
-2.07 (-0.60%) |
USD 15.68B |
| INCY | Incyte Corporation |
-5.83 (-7.86%) |
USD 14.29B |
| INSM | Insmed Inc |
-1.83 (-2.29%) |
USD 13.70B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| BUG | Global X Cybersecurity ET.. | 4.93 % | 0.00 % |
+0.49 (+1.40%) |
USD 0.80B |
| FPXI | First Trust International.. | 3.51 % | 0.70 % |
+0.86 (+1.40%) |
USD 0.14B |
| ZLU-U:CA | BMO Low Volatility US Equ.. | 2.22 % | 0.00 % |
+0.12 (+1.40%) |
N/A |
| ZLU:CA | BMO Low Volatility US Equ.. | 2.22 % | 0.33 % |
+0.29 (+1.40%) |
CAD 1.97B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 17.88% | 85% | B | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 17.88% | 85% | B | 87% | B+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | -80.04% | 16% | F | 7% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -80.04% | 16% | F | 7% | C- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -95.79% | 23% | F | 7% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -95.79% | 23% | F | 7% | C- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 50.76% | 78% | C+ | 87% | B+ | ||
| Dividend Return | 50.76% | 78% | C+ | 87% | B+ | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 477.32% | 17% | F | 7% | C- | ||
| Risk Adjusted Return | 10.63% | 60% | D- | 42% | F | ||
| Market Capitalization | 0.08B | 43% | F | 35% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
